Custirsen sodium: Phase III ongoing

OncoGenex said an IDMC recommended continuation of the open-label, international Phase III ENSPIRIT trial comparing weekly 640 mg IV custirsen plus IV Taxotere docetaxel given on day 1 of a 21-day cy...